-+ 0.00%
-+ 0.00%
-+ 0.00%

Ensysce Biosciences Reaches Key Enrollment Milestone in Phase 3 Trial of PF614 for Acute Pain

Reuters·01/28/2026 13:02:20

Please log in to view news